|Bid||283.00 x 800|
|Ask||305.00 x 800|
|Day's Range||284.46 - 299.55|
|52 Week Range||145.99 - 327.32|
|Beta (5Y Monthly)||0.84|
|PE Ratio (TTM)||196.13|
|Earnings Date||Nov 03, 2021 - Nov 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||257.88|
bluebird (BLUE) files BLA with the FDA for its gene therapy, betibeglogene autotemcel (beti-cel), in patients with transfusion-dependent ??-thalassemia.
Jason Hawthorne (Repligen): Repligen might fly under the radar, but it serves an important role in a fast-growing industry. The stock price reinforces that. The company has benefited from the adoption of biologic drugs over traditional small-molecule chemical compounds.
Verrica (VRCA) suffers a setback yet again as the FDA issues a CRL for its lead product candidate VP-102. Consequently, shares are trading down.